Over the last few weeks, we have continued our intense activity in MJN. On the 23rd and 24th, our partners Jordina and David flew to Dublin to assist the final of the Social Impact awards organized by the European Investment Bank Institute. After 6 months of selection, we were named among the 15 most important impact projects in Europe. Those were two days of great experiences and shared moments with other projects that work in favor of the Sustainable Development Goals (SDGs) in areas such as health, environment, social inclusion, fight against poverty… Finally, we didn’t get the prize but the mere fact of being nominated is very important for MJN since one of our goals is to work to have a positive impact among people with epilepsy and their entire environment.

Also on the 24th, Ernest, Xavier, and Salva attended the Impact Forum organized by Ship2B in Barcelona. The Ship2B Foundation focuses on detecting projects with a potentially high impact and helps them to maximize this positive impact on society. For us, it is a pride that Ship2b is investing in our project and we are grateful that they have helped us in recent years to grow within the health ecosystem of Barcelona. Throughout the day we were able to hold very interesting meetings with other projects, investors specialized in impact economics and other partners and contacts that, without a doubt, will be very interesting for the future of our project.

One of our goals is to work to have a positive impact among people with epilepsy

MJN-en-el-Impact-Forum-de-SHIP2B (4)

Salva, co-founder of MJN, talks about Marina’s story and her epilepsy at the Ship2B Impact Forum

It was a pleasure for us to talk about epilepsy and how MJN works to improve the lives of so many people in the world who live with the disease.

And this is nothing compared with what we have for November: we will attend the Dusseldorf Medica, in Brussels we are invited to explain our project and our financing needs for the upcoming years and we are already preparing a new trip to continue with our expansion to the United States in the next few months thanks to the invaluable help of ACCIÓ.

We keep moving!

Leave a Reply

Open chat
Contact with us now
Chat with Anna
¡Hola! 👋🏻
Soy Anna, ¿en qué puedo ayudarte?

The user who fills in the information requested in this form declares to be entitled to do so and is solely responsible for the accuracy and completeness of the data and information entered, expressly exonerating MJN NEUROSERVEIS of any liability that may arise for this entity on the occasion of the information provided through this form.

Yes, I accept

L’usuari que complimenta la informació requerida al present formulari declara estar legitimat per això i es fa responsable exclusiu de la veracitat i integritat de les dades i informació que introdueix, exonerant expressament a MJN NEUROSERVEIS de qualsevol responsabilitat que es pugi generar per aquesta entitat amb ocasió de la informació facilitat a través del present formulari.

Si, accepto

El usuario que cumplimenta la información requerida en el presente formulario declara estar legitimado para ello y se hace responsable exclusivo de la veracidad e integridad de los datos e información que introduce, exonerando expresamente a MJN NEUROSERVEIS de cualquier responsabilidad que pudiera generarse para esta entidad con ocasión de la información facilitada a través del presente formulario.

Sí, acepto

Save the date

The next Saturday 21st of November at 4 pm, you will be able to know first hand our product: mjn-SERAS.
mjn-SERAS is a healthcare product that sends a warning signal when the risk of epileptic seizures is high, to the affected person and their trusted contacts.

Sign up now!

    mjn-SERAS is a medical device with CE marking according to the European Directive 93/42/EEC and the Royal Decree RD. 1591/2009.
    Contraindications: Do not use the product if you suffer from an infection in the ear canal or if you suffer from a skin lesion in the vicinity of the product's area of influence.
    Considerations: This medical product works with an APP only on Android phones. The results tested are 96% sensitivity and 94% specificity.

    Save the date

    El próximo sábado 21 de noviembre a las 4 de la tarde, podrás conocer de primera mano nuestro producto: mjn-SERAS.
    mjn-SERAS es un producto sanitario que lanza una señal de aviso cuando el riesgo de crisis de epilepsia es elevado, a la persona afectada y a sus contactos de confianza.


      mjn-SERAS es un producto sanitario con marcado CE conforme a la Directiva Europea 93/42/EEC y el Real Decreto RD. 1591/2009.
      Contraindicaciones: No usar el producto en caso de padecer una infección en el canal auditivo o en caso de padecer una lesión cutánea en las proximidades del área de influencia del producto.
      Consideraciones: Este producto sanitario funciona con una APP solo en teléfonos Android. Los resultados testeados son 96% de sensibilidad y 94% de especificidad.